[Form 3] Zentalis Pharmaceuticals, Inc. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Form 3 initial statement: The reporting person, James B. Bucher, identified his relationship to Zentalis Pharmaceuticals, Inc. as a director and Chief Legal Officer and filed an initial Section 16 Form 3. The filing states no securities are beneficially owned by the reporting person and attaches an exhibit noting a power of attorney. The form is an initial disclosure of ownership status rather than a transaction report.

Insights

Securities Compliance Analyst

TL;DR: Initial Section 16 filing reports zero beneficial ownership and documents authority arrangements; routine disclosure with no trading impact.

This Form 3 identifies James B. Bucher as a director and officer (Chief Legal Officer) of Zentalis Pharmaceuticals and states explicitly that he beneficially owns no securities of the issuer. The filing includes an exhibit referencing a power of attorney. From a compliance standpoint, this is a standard initial disclosure establishing reporting status and does not disclose any holdings or derivative positions that would trigger market impact or immediate Section 16 reporting obligations for trades.

Corporate Governance Specialist

TL;DR: Governance disclosure confirms officer/director status with no beneficial ownership reported; informational only.

The document serves to record the reporting person's relationship to the company and to confirm absence of beneficial ownership. It does not present material changes to capital structure, insider holdings, or related-party transactions. The inclusion of a power of attorney exhibit is noted but no authority details or implications are provided within the body of the filing. Overall, the filing is administrative and unlikely to affect investor assessments absent subsequent ownership changes.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Bucher James B

(Last) (First) (Middle)

C/O ZENTALIS PHARMACEUTICALS, INC.

10275 SCIENCE CENTER DRIVE, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/18/2025

3. Issuer Name and Ticker or Trading Symbol
Zentalis Pharmaceuticals, Inc. [ ZNTL ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ James B. Bucher	09/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Form 3 filed for ZNTL indicate about James B. Bucher's holdings?

The Form 3 states no securities are beneficially owned by James B. Bucher.

What role does the reporting person hold at Zentalis Pharmaceuticals (ZNTL)?

The filing identifies James B. Bucher as a director and the company's Chief Legal Officer.

Does the Form 3 disclose any derivative securities or option positions for ZNTL?

No. The filing contains no entries for derivative securities or underlying shares; it explicitly states no beneficial ownership.

Is there any exhibit attached to the Form 3 and what is it?

Yes. The filing references Exhibit 24, which is a power of attorney.

Does this Form 3 report any transactions in ZNTL securities?

No. The Form 3 is an initial ownership statement and reports that the reporting person owns no securities.